@article{c544ba0ada9844b0bf6093c051bbf30b,
title = "Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders",
author = "Jennifer La and Wu, \{Julie Tsu Yu\} and Westyn Branch-Elliman and Linden Huhmann and Han, \{Summer S.\} and Mary Brophy and Do, \{Nhan V.\} and Lin, \{Albert Y.\} and Fillmore, \{Nathanael R.\} and Munshi, \{Nikhil C.\}",
note = "Funding Information: Conflict-of-interest disclosure: W.B.-E. reported receiving grants (site PI for multicenter study) from Gilead Sciences and funds to institution and grants from VA Health Services Research and Development Service outside of the submitted work. M.B. reported receiving nonfinancial support from the VA Cooperative Studies Program during the conduct of the study. A.Y.L. reported receiving grants from the Department of Defense outside of the submitted work. N.C.M. reported receiving personal fees from Bristol Myers Squibb, Janssen, Amgen, Takeda, OncoPep, AbbVie, Karyopharm, Novartis, Legend, Raqia, Adaptive Biotechnology, and Pfizer outside the submitted work; in addition, N.C.M. had a patent for OncoPep licensed and held stocks in C4 Therapeutics. The remaining authors declare no competing financial interests. Funding Information: Funding support for this article was provided by the VA Cooperative Studies Program; VA Merit Review Award (1I01BX001584); National Cancer Institute (P01-155258-07, P50-100707); American Heart Association (870726); Stanford Cancer Institute (SPO \#216151). ",
year = "2022",
month = aug,
day = "18",
doi = "10.1182/blood.2022016317",
language = "English",
volume = "140",
pages = "782--785",
journal = "Blood",
issn = "0006-4971",
publisher = "Elsevier B.V.",
number = "7",
}